Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06SJZ
|
||||
| Former ID |
DIB001705
|
||||
| Drug Name |
XB-947
|
||||
| Synonyms |
XR-469R; (+)-2(R)-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt; (R)-(+)-XK-469
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H15ClN2O4
|
||||
| Canonical SMILES |
CC(C(=O)OC)OC1=CC=C(C=C1)OC2=CN=C3C=CC(=CC3=N2)Cl
|
||||
| InChI |
1S/C18H15ClN2O4/c1-11(18(22)23-2)24-13-4-6-14(7-5-13)25-17-10-20-15-8-3-12(19)9-16(15)21-17/h3-11H,1-2H3
|
||||
| InChIKey |
NPUWJNOFOGQLSR-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II, beta isozyme | Target Info | Modulator | [2] | |
| PANTHER Pathway | DNA replication | ||||
| References | |||||
| REF 1 | A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 August; 44(12): 1684-1692. | ||||
| REF 2 | XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.